

Invitation to the 2024 Summit on Innovations in Drug Development – Complimentary Half-Day Seminars in San Francisco, CA

This event is an excellent opportunity for you to gain cutting-edge insights into drug development and connect with fellow industry professionals.

SAN FRANCISCO, CA, UNITED STATES, September 25, 2024 /EINPresswire.com/ -- Triclinic Labs and ELDICO Scientific AG are excited to announce the 2024 Summit on Innovations in Drug Development, a series of exclusive, complimentary half-day seminars designed for professionals in the pharmaceutical and biotechnology industries. The event will take place at four premier locations across the U.S., offering attendees an opportunity to explore innovative strategies and technologies that can transform their drug development programs.



Triclinic Labs - The industry's choice for comprehensive materials analysis and solid-state chemical development

The San Francisco summit will feature renowned industry experts sharing groundbreaking



The 2024 Summit on Drug Development is a unique platform for professionals to engage with cutting-edge technologies and strategies that are reshaping the future of pharmaceuticals."

David E. Bugay, Ph.D.

insights on electron diffraction and its applications in pharmaceuticals, cutting-edge approaches for rapidly developing amorphous spray-dried formulations, and critical considerations for protecting intellectual property in drug development.

Event Details and Locations: Tuesday, October 15th, 2024 Hilton San Francisco Airport Bayfront 600 Airport Blvd, Burlingame, CA 94010 Parking will be provided. 9:00 - 9:45 am | Leveraging Electron Diffraction in Pharmaceutical Development

9:45 - 10:30 am | Case Studies: Using Electron Diffraction in Pharma

10:30 - 10:45 am | Break

10:45 - 11:45 am | Protecting Your Pharmaceutical Intellectual Property

11:45 - 12:30 pm | Rapid Screening and Development of Amorphous Solid

Dispersions (ASD)

12:30 - 1:30 pm | Lunch, Networking, and Discussions



Click here for the FULL Event Agenda with abstracts and bios.

Please visit the event webpage for more details and to <u>register for the San Francisco Drug</u> Development Summit.

Why Attend?

This summit is a unique opportunity to learn from leading experts about the latest advancements in drug development. Attendees will have the chance to:

- Discover how electron diffraction is revolutionizing pharmaceutical applications.
- Gain insights into rapid screening and development of amorphous spray-dried formulations.
- Understand key intellectual property strategies to protect their innovations.

Space is limited for this free event! Please RSVP by October 10th, 2024, to secure your spot at this insightful event.

Contact Information:

For additional information or questions, please contact us:

Phone: (US) 765-588-6200 Email: rfi@tricliniclabs.com

We look forward to welcoming you to the San Francisco 2024 Summit on Drug Development!

About Triclinic Labs, Inc.:

Triclinic Labs is a leader in the field of solid-state chemistry, materials science, and pharmaceutical development. We provide cutting-edge analytical services and solutions to advance drug discovery and development. https://tricliniclabs.com

About ELDICO Scientific AG:

ELDICO Scientific AG specializes in electron diffraction technology for nanocrystalline substances, offering unique solutions that advance research and development in various scientific fields. https://www.eldico-scientific.com/

Shawn Comella, CEO Triclinic Labs, Inc. +1 765-588-5624 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/746433468 EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.